In this study, we designed and validated a platform for ultrasound (US) and microbubble (MB)-mediated delivery of FDA-approved pegylated poly lactic-co-glycolic acid (PLGA) nanoparticles (NPs) loaded with anticancer microRNAs (miRNAs) to deep tissues in a pig model. Small RNAs have the ability to reprogram tumor cells and sensitize them to clinically used chemotherapy. However, to overcome their short intravascular circulation half-life and achieve controlled and sustained release into tumor cells, anticancer miRNAs need to be encapsulated into NPs. Moreover, focused US combined with gas-filled MBs provides a safe and noninvasive way to improve the permeability of tumor vasculature and increase the delivery efficiency of drug-loaded nanocarriers. A single handheld, curvilinear US array was used in this study for image-guidance and therapy with clinical-grade SonoVue MBs. First, we validated the platform on phantoms to optimize the MB cavitation dose based on acoustic parameters, including peak negative pressure, pulse length, and pulse repetition frequency. We then tested the system in vivo by delivering PLGA-NPs co-loaded with antisense-miRNA-21 and antisense-miRNA-10b in pig liver and kidney.
Introduction
MicroRNAs (miRNAs or miRs) are small, non-coding regulatory molecules responsible for mediating several signaling pathways, which are crucial for cancer initiation and progression, invasion and metastasis, and drug resistance [1] . Abnormal miRNA regulation caused by genetic or epigenetic mechanisms may result in oncogenic effects [2] . Counterbalancing the function of up-or downregulated miRNAs via exogenous manipulation with synthetic sense-miRNA or antisense-miRNA (AmiRNA or AmiR), has shown anticancer treatment effects in vitro and in vivo [3] , [4] .
A major challenge of using RNA interference for cancer therapy is the low circulation half-life of naked synthetic small RNAs when they are injected into the bloodstream, which is due to abundant nucleases [5] , [6] . A viable strategy to circumvent the rapid intravascular degradation is to shield the miRNAs by enclosing them into nanocarriers [3] . Encapsulation of therapeutic agents into nanoparticles (NPs), including liposomes and polymer or albumin-based NPs, has been extensively investigated in cancer treatment [7] . Importantly, NPs may be designed to enhance the drug biodistribution, accumulation kinetics, and sustained release profile by taking advantage of the tumor enhanced permeability and retention (EPR) effect, i.e. the abnormal permeability of the cancer vasculature that allows larger NPs, which are normally prevented from extravasating, to reach the cancer tissue. This targeted delivery mechanism is particularly interesting as it offers the possibility to increase the therapeutic efficacy of intravenously administered anticancer formulations while minimizing adverse effects in healthy organs due to unintended drug accumulation [8] . Nevertheless, EPR effect-based targeting is highly sensitive to pathophysiological factors like abnormal tumor vascular morphology, variable blood flow rate, and high interstitial fluid pressure, leading to low delivery efficiency and highly heterogeneous drug distribution [9] .
Focused ultrasound (US) combined with gas-filled microbubbles (MBs) provides a safe and noninvasive way to increase the tumor vascular permeability through a process named sonoporation [10] , [11] . The oscillating US field impinging upon the bubble surface creates stable compressions and expansions at lower acoustic pressures (tens to hundreds of kilopascals) and causes violent MB rupturing if the pressure is strong enough (up to several megapascals). The two phenomena are referred to as stable and inertial cavitation, respectively. MB cavitation promotes the formation of fluid microjets, shockwaves, streaming, and cavitation forces, which in turn give rise to shear stresses on the cellular membrane and vascular barrier. These forces breach the blood vessel walls and facilitate NP extravasation, increasing vascular porosity and hence overcoming the high variability of the EPR effect [12] - [17] . Additionally, focused US enables targeted and controlled drug delivery with high spatial selectivity, as the US-induced effects are spatially limited to the US focus, which can be directed to any desired target region. Previous studies have demonstrated that US and MB therapy is effective to enhance the delivery of large-sized particles or molecules for treatment of a number of diseases including hepatocellular carcinoma [4] , non-resectable pancreatic cancer [18] - [20] , breast cancer metastasis in the brain [21] , and Alzheimer's disease [22] .
A system for image-guided US and MB-mediated targeted delivery of miRNA-loaded nanocarriers was implemented and tested in mice by Wang et al. [23] , and subsequently used in a longitudinal study investigating the effect of two complementary miRNAs (miR-122 and AmiR-21) combined with doxorubicin in drug-resistant hepatocellular carcinoma [24] . miRNAs were loaded into FDA-approved pegylated poly lactic-co-glycolic acid (PLGA) NPs [25] , and US-induced inertial cavitation of circulating MBs was demonstrated to significantly increase the amount of delivered miRNAs and to decrease the tumor growth after repeated cycles of combined therapy [24] . In the current study, we used PLGA-NP co-loaded with AmiR-21 and AmiR-10b, two antisense miRNAs antagonizing the function of endogenous miR-21 and miR-10b, respectively. These miRNAs have been reported to be significantly upregulated in a number of malignancies and to play a role in preventing apoptosis and promoting tumor migration and metastatic spread [1] , [26] . Silencing the expression of miR-21 and miR-10b through administration of antagonizing miRNAs was shown to elicit substantial reduction of tumor growth [3] .
The objective of this work was to design and validate a platform for targeted delivery of miRNA-loaded NPs to deep tissues in large animal models, as a further step toward clinical translation. In this platform, a single diagnostic US transducer array was used for image-guidance and therapy in combination with clinical-grade SonoVue MBs (Bracco Imaging S.p.A., Milan, Italy). The system was first tested on phantoms to optimize relevant acoustic parameters for maximizing inertial cavitation dose. miRNA-loaded PLGA-NPs were administered systemically in combination with highly fluorescent semiconducting polymer nanoparticles (SPNs), and US treatment was delivered to the liver and kidney of healthy pig models to validate the feasibility of the setup in vivo. Uptake of PLGA-NPs was assessed by quantifying the levels of delivered therapeutic miRNAs by quantitative reverse transcription polymerase chain reaction (qRT-PCR), and immunofluorescence (IF) microscopy of SPNs was performed to confirm extravasation of NPs and their presence into the parenchyma.
Materials and methods

Delivery platform and ultrasound system
The implemented platform for targeted delivery of miRNA-loaded NPs to deep tissues in large animal models is schematically depicted in Figure 1A . MBs and NPs are co-administered intravenously, and MB cavitation, induced by the focused US beam, increases the vascular permeability in the target region and facilitates transport of NPs out of the vascular compartment. The extravasated NPs are then endocytosed by parenchymal cells and release their cargo of miRNA.
A single handheld, curvilinear array transducer (C5-2v; Verasonics Inc., Redmond, WA, USA) was used with a Vantage 256 research scanner (Verasonics Inc.) for image-guided therapy. During the animal experiments, the probe was housed in a custom 3-D printed holder and mounted on a jointed flex-arm stand (Dino-Lite MS-52B; AnMo Electronics Corp., Taipei, Taiwan). The positioning system enables comfortable freehand scanning and allows for probe fixation in the desired target location by locking the arm joints. The custom holder allows for rotation of the probe in the elevation direction at angular increments of 2.5 ( Figure   1B) .
A B-mode imaging sequence consisting of 13 unfocused emissions steered between ± 9 • with a center frequency of 4 MHz was used for image guidance (Figure 1C ) [27] , [28] . The beamformed images were displayed with a dynamic range of 60 dB and a frame rate of 6 frames/s. The mechanical index (MI) of the B-mode emissions was 0.15 to avoid nonspecific destruction of bubbles from the imaging pulses.
Therapy was delivered using a focused beam with an F-number of 1.2 and a center frequency of 2
MHz. The emitted acoustic pressure was measured in the XZ and YZ planes with a focus at 70 mm using a needle hydrophone (HNC-0500; Onda, Sunnyvale, CA, USA) in degassed water ( Figure 1D) . The full width at half maximum was 1.9, 2.9, and 21.8 mm in the X, Y, and Z directions, respectively. For calibration, the peak negative pressure was measured with increasing excitation voltage and derated with an attenuation factor of 0.5 dB/(cm MHz).
Microbubbles
Clinically approved SonoVue contrast agent was used for all the phantom and animal experiments. The MBs consist of a stabilized sulfur hexafluoride gas core surrounded by a phospholipid shell, with diameter in the range of 2 to 9 μm [29] . The contrast agent was resuspended in sterile 0.9% physiological saline and diluted to obtain the desired concentration.
Phantom experiments
A phantom study was performed to determine the effects of acoustic parameters on the MB cavitation. A concentration of approximately 10 7 MB/ml was used. The solution was circulated in a 4-mm diameter flow channel embedded in tissue-mimicking material (Model 527; ATS, Bridgeport, CT, USA) using a flow pump (ISM596D; IDEX, Oakharbor, WA, USA). A mean velocity of 1.2 mm/s was maintained. The phantom setup is depicted in Figure 2A . The US probe was positioned at a distance of 70 mm from the vessel, and a focused US beam was used to induce MB cavitation. Peak negative pressure, pulse length, and pulse repetition frequency (PRF) of the therapy pulse were varied as reported in Figure 2B . Two hundred pulses were delivered for each set of acoustic parameters.
To measure the inertial cavitation dose (ICD), the broadband emission generated by inertial cavitation events was detected by using the same transducer array. The root mean square (RMS) intensity of the recorded echoes was calculated (over the frequency range 5.5 MHz ± 150 kHz) and integrated over the number of delivered pulses. The measurement was first performed on a saline-filled vessel to estimate the baseline noise floor, and then repeated with circulating MBs. The baseline noise floor was then subtracted from the RMS intensity resulting from MB cavitation to obtain the ICD [30] . The data processing and ICD calculation were performed in MATLAB (The MathWorks, Inc., Natick, MA, USA).
Analysis of variance (ANOVA) was used to assess the presence of a significant effect of each parameter on the measured ICD. A Wilcoxon signed-rank test was used for pairwise comparisons within each set of acoustic parameters. All statistical tests were performed in RStudio 1.1.442, and statistical significance was considered for p < 0.05. 
Nanoparticle synthesis
AmiR-21 and AmiR-10b-loaded PLGA-NPs
PLGA-NPs loaded with AmiR-21 and AmiR-10b were prepared using a double emulsion solvent evaporation technique as described previously [3] , [23] . In brief, the miRNAs (10 nmol) were complexed with spermidine in an N/P ratio of 15:1 in DNAse/RNAase free water for 15 min at room temperature. The miRNA-spermidine complex was added dropwise to the stirred solution of FDA-approved pegylated PLGA polymer (10 mg) dissolved in dichloromethane (DCM, 1 ml) containing 3% Span-80. Successively, the complex was sonicated for 60 sec at 40% amplitude (SFX-150; Branson Ultrasonics, Danbury, CT, USA) in an ice bath to form the first emulsion. The mixture was added to 5 ml of emulsifying water (Tween-80, 1% w/v) and sonicated at 40% amplitude in an ice bath for 60 sec to form the second emulsion, followed by stirring for 3 h to facilitate evaporation of the DCM. The NPs were then sterile filtered using a 0.45-μm syringe filter (Whatman PURADISC 25 AS; GE Healthcare Life Sciences, Pittsburg, PA, USA). Excess surfactants and free miRNAs were removed by centrifuging the NPs three times in sterile DNAse/RNAase free water (Invitrogen, Grand Island, NY, USA) at 3000 rpm using an ultracentrifuge filter device with 100 kDa MWCO Membrane (Amicon Ultra; Merk Millipore, Burlington, MA, USA). The size and Zeta-potential of the PLGA-NPs were measured using a Zetasizer Nano ZS90 sizing device (Malvern Panalytical Ltd., Malvern, U.K.). NP concentration was quantified with nanoparticle tracking analysis (NTA) by NanoSight NS300 (Malvern) using 10 mg of PLGA dissolved in 3.3 ml of deionized water. Gel electrophoresis was used to determine encapsulation and loading efficiency of miRNAs after extracting the loaded miRNAs from a fixed amount of NPs, as well as from the washed solution.
SPNs
SPNs are fluorescent NPs made of organic and biocompatible polymer material with high brightness and controllable dimensions. We synthesized these particles with characteristics similar to the PLGA-NPs and used them as a model nanocarrier to confirm NP extravasation via IF confocal microscopy. SPNs were prepared following a protocol described previously [31] with minor modifications. Briefly, 15 mg of 1,2-
Distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)-2000] (ammonium salt;
DSPE-mPEG) were dissolved into 1 ml of DCM solution containing 0.25 mg/ml of poly [2,7-(9,9- dioctylfluorene)-alt-4,7-bis(thiophen-2-yl)benzothiadiazole] (PFODBT). The mixture was poured into distilled-deionized water (10 mL) under continuous sonication with an ultrasonic sonifier (Branson Ultrasonics) at a power output of 6 W RMS for 10 min on ice. DCM was evaporated at 45°C under nitrogen atmosphere. Finally, the aqueous solution of SPNs was filtered through a 0.22 μm polyvinylidene fluoride membrane filter, and particle concentration was quantified by NTA.
Animal preparation
The experimental protocol for the animal study was approved by the Institutional Animal Care and Use and fasted overnight prior to the compound administration and imaging procedure. Reverse-osmosis water delivered through both an automatic watering system and in a bowl was made available at all times.
The animals were anesthetized with intramuscularly administered tiletamine HCL and zolazepam HCL (8 mg/kg; Telazol; Pfizer, New York, NY, USA), intubated, and kept under inhalant 2-4% isoflurane in oxygen (2 l/min). Vascular access was created via an intravenous catheter inserted in the marginal ear vein. Pigs were administered acetylsalicylic acid (Aspirin; Wedgewood, Swedesboro, NJ, USA) intravenously (3.5 mg/kg) 5 min prior to NP injection. Vital signs including heart rate, respiratory rate, blood pressure, oxygen saturation, end-tidal CO2 pressure, EKG, and body temperature were monitored during the entire procedure with an anesthesia and monitoring system (SurgiVet, Dublin, OH, USA).
Drug delivery protocol
Prior to the therapy procedure, the liver and right kidney were imaged from a subcostal view. Easilyaccessible regions were identified in the two organs at a depth of approximately 70 mm, and the two imaging windows were marked on the skin. A solution of PLGA-NPs co-loaded with AmiR-21 and AmiR-10b (8 ml; 8 × 10 11 NP/ml) and SPNs (3 ml; 5.13 × 10 13 NP/ml) was administered with a bolus injection. A volume of 25 ml SonoVue was diluted with sterile 0.9% saline in a 40-ml solution. The MB solution was continuously infused at a rate of 16.67 l/s for the entire duration of the therapy procedure (approximately 40 min).
Focused US treatment was initiated 2 min after the MB infusion was started to ensure a steady state of MB perfusion. The treatment was performed first in the liver and subsequently in the right kidney. A 10cycle focused US pulse was used for drug delivery with a derated in-situ peak negative pressure of 5. 
In vivo experiments and tissue collection
We preliminarily tested the US platform in two animals to validate US imaging parameters and probe positioning to target liver and kidney. It was not possible to analyze tissues from these animals due to the inability to identify the therapy regions at necropsy, as discussed below.
A third animal was anesthetized, administered an injection of miRNA-loaded PLGA-NPs, and recovered A liver tissue sample was obtained from a fifth animal that did not receive any injection or US treatment.
This sample was used for a baseline quantification of endogenous miRNA (miR-122) and considered as a negative control.
MicroRNA quantification
Harvested samples for miRNA quantification were snap-frozen on dry ice immediately after resection. The levels of delivered therapeutic AmiR-21 and AmiR-10b were evaluated by using qRT-PCR. Samples of tissue of 100 mg were homogenized using a PRO250 tissue homogenizer (PRO Scientific, Oxford, CT, USA) in 300 l lysis buffer for 3 min. Total RNA (mRNA and miRNA) was isolated from the lysates using mirVana miRNA Isolation Kit (Life Technologies, Grand Island, NY, USA) adopting the total RNA extraction procedure according to the manufacturer's protocol.
For miRNA quantification, 50 ng of total RNA was reverse transcribed using RT-primers (Life Technologies) for AmiR-21 and AmiR-10b using a custom ordered TaqMan kit and a microRNA Reverse Transcription Kit (Life Technologies). RT-PCR was performed using cDNA (5 ng equivalent of total RNA) combined with TaqMan RT-PCR reagents (primer and probe mix) of AmiR-21 and AmiR-10b. qRT-PCR was performed by 2 min incubation at 50 C followed by activation of the DNA polymerase at 95 C for 10 min, 60 cycles of 95 C for 15 sec, and 60 C for 60 sec in a Bio-Rad CFX96 Touch TM Real-Time PCR Detection System (Bio-Rad, Hercules, CA). The presence of AmiR-21 and AmiR-10b was calculated using the 2 -CT method [32] . The RT-PCR quantification was repeated three times for each analyzed sample. The miRNA levels were normalized to the endogenous level of miR-122 in a control liver sample from the animal that was administered neither NPs nor US and MB therapy.
Immunofluorescence staining
Tissue samples for IF analysis were fixed in 4% paraformaldehyde overnight at 4 C, immersed in a 30% sucrose solution for cryoprotection, and frozen at -80 C. Tissues were then embedded in optimal cutting temperature media (OCT; Fisher Scientific, Whitby, Ontario, Canada) and cryosectioned in slices of 10 m thickness. The sections were stained for F-actin (using phalloidin) and vascular endothelial cell marker CD31 for visualizing the cytoskeleton and blood vessels, respectively.
The slices were rinsed in phosphate-buffered saline (PBS) for 10 min, permeabilized in 0.5% Triton-X 100 in PBS, and incubated in a blocking solution of 3% bovine serum albumin (Sigma, St. Lousi, MO, USA), 3% normal goat serum (Sigma), and 3% normal donkey serum (Sigma) for 60 min at room temperature.
The samples were then incubated with a rabbit-anti-human CD31 primary antibody (1:100; Abcam, Cambridge, MA, USA) at 4 C overnight in a humidifying chamber. Samples were then incubated with a goat anti-rabbit Alexa Fluor 488 IgG secondary antibody (1:250; Invitrogen) and Alexa Fluor 633-phalloidin (1:100; Invitrogen) for 30 min. Samples were mounted in aqueous mounting media (BiogeneX, San Ramon, CA, USA) and imaged with a LSM710 metaconfocal microscope (Carl Zeiss GmbH, Jena, Germany) at 20X magnification. A tiled confocal micrograph was obtained using a motorized staged controlled by the microscope acquisition software (AxioVision; Carl Zeiss). Image analysis was performed in Fiji 2.0.0 [33] .
Hematoxylin and eosin staining
Kidney and liver samples were fixed in 10% neutral buffered formalin at room temperature, routinely processed, embedded in paraffin, and sectioned with a microtome into 5 m thick slices for routine hematoxylin and eosin (H&E) staining. Tissue assessment was performed blindly by a veterinary pathologist (JGVM).
Results
Inertial cavitation dose measurement in phantom
The results of the ICD measurements in phantom with varying acoustic parameters are reported in Figure   2C , 2D, and 2E. In each plot, the ICD was normalized to the mean ICD for the lowest value of each parameter, i.e. peak negative pressure of 0.13 MPa, pulse length of 2 cycles, and PRF of 1 Hz.
The ICD was significantly influenced by all the parameters tested (ANOVA; p < 0.0001). Peak negative pressure and pulse length had the highest effect on cavitation, with a 33-and 38-fold maximum increase for the pressure and pulse length, respectively. A plateau was reached for pressure above 2.57 MPa (Figure 2C) , and no statistical difference was found between 2.57, 3.85, and 5.34 MPa (p = 0.89 for 2.57 and 3.85; p = 0.71 for 2.57 and 5.34; n = 4). Similarly, there was no statistical significance between pulse lengths of 5, 10, and 20 cycles (Figure 2D ; p = 0.312 for 5 and 10; p = 0.061 for 5 and 20; n = 4). Conversely, the PRF caused a decreasing trend on the measured ICD, although the difference was minimal (< 2-fold maximum decrease). No statistical significance was found between 4, 10, and 20 Hz (Figure 2E ; p = 0.216 for 4 and 10; p = 0.112 for 4 and 20; n = 4). 
Nanoparticle characterization
AmiR-21 and AmiR-10b-loaded PLGA-NPs
Particle characterization results are reported in Figure 3C) . The zeta potential of PLGA-NPs was in the range -20 to -40 mV (Figure 3D) , likely due to the anionic nature of antisense-miRNA incorporated in the NPs. The average size and Zeta-potential of PLGA-NPs were 115.3  18 nm and -32.2  2.8 mV, respectively. The final particle concentration quantified by NTA was 3.3×10 12 NP/ml (Figure 3B) . (Figure 3D) . The average size of SNPs was 116  5 nm (Figure 3C) . The maximum excitation/emission wavelength was 523/630 nm. The data reveal that the presence of DSPE-mPEG slightly affects the size of SPNs but increases their zeta potential, possibly yielding improved aqueous stability.
To test the in vitro cell-labelling efficiency of SPNs, breast cancer cell lines (SKBR3 and MDA-MB-231)
were used as a model. After incubation of cells with SPNs at a concentration of 50 μg/ml at 37 °C for 8 h, live cells were imaged by fluorescence microscopy (Figure 3E) . Bright red fluorescence of SPN clusters was located in the cytoplasm rather than limited to the cell membrane, indicating uptake by the cells.
Delivery of AmiR-21 and AmiR-10b-loaded PLGA-NPs
RT-PCR quantification of exogenous AmiR-21 and AmiR-10b delivered to liver and kidney in the treated pigs is reported in Figure 4 along with the biodistribution at 4 h and 24 h time points. The miRNA levels are normalized to the level of endogenous miR-122 in the liver of a negative control animal that received neither NP injection nor US treatment. The levels of AmiR-21 in the liver (Figure 4A ) increased 991-fold in response to PLGA-NP injection alone (untreated region) and 1884-fold after US and MB therapy (treated region), compared to the control animal. The level of AmiR-10b in the liver increased 89-fold due to NP injection and 245-fold post US treatment, compared to the control animal. Therefore, US and MB-mediated delivery yielded a 1.9-and 2.7-fold increase of the two exogenous miRNAs in liver. Levels of AmiR-21 quantified in the kidney (Figure 4B ) increased 160-fold due to NP injection and 598-fold in response to US treatment, while the levels of AmiR-10b increased 15-and 42-fold for the two cases. Hence, the increase due to US and MB treatment was 3.7-and 2.8-fold for the two exogenous miRNAs in the kidney.
The biodistribution of AmiR-21 in Figure 4C 
Immunofluorescence analysis
To confirm that increased level of exogenous miRNA was due to enhanced delivery of PLGA-NPs in response to the US and MB-mediated therapy, we performed IF confocal microscopy of SPNs as a model system to mimic the miRNA-loaded PLGA-NPs. Representative IF images are shown in Figure 5 for both a treated (Figure 5A) and untreated (Figure 5B ) liver region. The IF images confirmed presence of SPNs in the liver parenchyma and in regions peripheral blood vessels, indicating extravasation. Increased presence of SPNs was also noticed in the treated liver sample with respect to the untreated region, although we did not perform a quantitative assessment of the fluorescence levels due to the unequal distribution of the IF signal in various tissue region.
Histological analysis
Representative H&E-stained sections of pig liver and kidney tissues are shown in 
Discussion
In this study, we reported the design and validation of a platform for US and MB-mediated targeted delivery of FDA-approved PLGA-NPs loaded with anticancer AmiR-21 and AmiR-10b in a large animal model. The results showed enhanced miRNA delivery in the liver and kidney, with an increase in quantified miRNA for cardiac gene transfection in pigs [35] . Importantly, US therapy was recently used in clinical trials combined with drug-loaded MBs to investigate its feasibility in the treatment of pancreatic or liver cancer patients [19] , [36] . Here, we use PLGA-NPs as a delivery vector rather than encapsulating the therapeutic miRNAs directly into the MBs to increase the miRNA circulation half-life and improve the drug release profile. To the best of our knowledge, this is the first study demonstrating a platform for US-mediated delivery of miRNA-loaded PLGA-NPs to deep tissues (70 mm) in large animals.
The objective of our study was to translate the drug delivery platform that we previously designed and tested in mice [23] for use in large animal models, as a further step toward clinical translation. The platform was implemented on a commercially available scanner using a single curved array transducer for imageguided therapy and with clinical-grade MBs. We chose a pig model to test our system in vivo primarily because of anatomical similarities with humans, in particular with respect to the position and depth of liver and kidney, and due to our prior expertise with this animal model. However, it was important to determine if sufficient inertial cavitation of circulating MBs could be achieved at depth by using a diagnostic ultrasound transducer. Therefore, we first performed a phantom study to optimize the relevant acoustic parameters for maximizing ICD. The optimized parameters were then used for the in vivo experiments. We observed a plateau-like behavior for the measured ICD at higher pressure, pulse length, and PRF. A possible explanation for this effect is that MBs were destroyed in a larger volume and/or faster while not being replenished quickly enough to increase the ICD. However, this situation is not reflective of the behavior in vivo, where MBs are replenished through a more complex vasculature.
RT-PCR quantification showed a 1.9-and 2.7-fold increase in the liver and 3.7-and 2.8-fold increase in the kidney for exogenous AmiR-21 and AmiR-10b, respectively. The results are comparable to the amount of miRNA quantified in hepatocellular carcinoma xenografts in mice after US treatment [23] . miRNA levels were overall higher in the liver due to clearance of the NPs in this organ. We show that at 24 h there is decreased exogenous AmiR-21 in the liver, kidney, and heart with respect to the level at 4 h, while the miRNA level increased substantially at 24 h in the lung and spleen. This may be due to the uptake of PLGA-NPs by immune cells, which accumulate in these organs. To confirm the presence of NPs in the liver parenchyma, we performed IF microscopy of SPNs. Importantly, the SPNs were located peripherally to the endothelial marker CD31, supporting the hypothesis of transvascular transport and entry of NPs in the extravascular compartment.
We acknowledge the presence of several limitations in our experimental design. First, a single animal was used for quantification of delivered miRNA in the target regions, therefore we could not demonstrate reproducibility of the results. However, we observed a similar delivery effect in two different organs (kidney and liver) within the same animal. Additionally, the delivered antisense miRNAs are not available in the animal system under normal conditions, hence the observed variations may not be attributable to other endogenous confounding factors. We performed the treatment on a total of four animals. The first three pigs received US therapy in the liver only and were euthanized 24 h post NP administration. We performed an US-guided injection of India ink immediately after the treatment to mark the targeted region and facilitate its identification ex vivo. However, we could not find traces of dye at necropsy and were unable to locate the treated area in the liver, possibly due to the fast clearance of ink from the organ. For this reason, we modified the experimental protocol to euthanize the fourth pig at 4 h post NP administration. We kept the animal under anesthesia for the whole duration of the treatment to avoid significant organ displacement and injected a solution of Matrigel with ICG dye. The Matrigel solution solidifies immediately at 37 C becoming a gelatinous matrix that is not quickly cleared by the liver. In the kidney, we targeted the lower pole to facilitate localization based on the anatomy of the organ.
A second limitation of our study was that only healthy animals were used, due to the challenges of producing a cancer model in pigs. Our future work will focus on delivering miRNA-loaded PLGA-NPs in client-owned dogs with advanced liver cancer. While we expect increased levels of delivered miRNAs in cancer compared with healthy tissue due to the more fragile and leakier tumor vasculature, challenges may arise from hypovascularized or necrotic regions preventing circulating MBs and NPs to reach the target area.
Finally, our current implementation did not include measurement of cavitation signals during the administration of US therapy in vivo. Future implementations will include real-time cavitation monitoring to ensure optimal sonication conditions over the treatment period.
In conclusion, through this study we show the design and validation of a single-probe US platform for targeted delivery of miRNA-loaded PLGA-NPs to deep organs in large animal models. The implemented platform represents a step further toward translation of this targeted drug delivery system in humans. 
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